84 search results for: asthma
ERS 2024 | Can Biologics Affect Airway Remodeling?
Dr Mario Castro presents the latest clinical data on biologics showcasing their effect on airway remodeling parameters and airway hyperresponsiveness in patients with severe asthma.
ERS 2024 | Fireside Chat: What Is the Potential for Disease Modification in the Era of Biologics?
Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss disease modification in severe asthma, including what disease modification is, how it can be identified, and how the advent of biologics may bring about disease modification.
ERS 2024 | View From the Clinic: What Are the Clinical Consequences of Airway Remodeling?
Professor Klaus Rabe shares a patient case highlighting the burden of disease associated with airway remodeling and discusses practical aspects of identifying and managing airway remodeling in severe asthma patients with Professor Porsbjerg and Dr Castro.
ADVENT at ERS 2024
The ADVENT program will present four symposia sharing the latest science in asthma and COPD at the 2024 European Respiratory Society (ERS) Congress. Visit Booth #A4.02 to learn more about ADVENT.
Celeste Porsbjerg, MD, PhD
Professor of Severe Asthma, Bispebjerg Hospital Copenhagen, Denmark
Nicole Chase, MD
Associate Professor of Medicine, University of Minnesota; Physician Minneapolis VA Health Care System; Partner, St. Paul Allergy & Asthma, PA
ADVENT at EAACI PAAM 2025
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation processes underlying pediatric asthma, atopic dermatitis, and eosinophilic esophagitis.
Simon Couillard, MD, MSc
Professor Couillard is a respirologist and the Québec Lung Association Chair of Respiratory Research at the Université de Sherbrooke, Canada. He leads a team investigating ways to use biomarkers to predict and prevent asthma attacks and improve asthma management.
Njira Lugogo, MD
Dr. Lugogo is a Professor of Medicine in the Division of Pulmonary, Critical Care Medicine and is the Director of the Michigan Medicine Asthma Program. She is also the Program Director of INHALE, a statewide collaborative quality improvement program that focuses on improving the care of patients with asthma and COPD in Michigan.
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.
Miguel Lanz, MD, FAAAAI
Lanz Allergy, Asthma & Immunology AAADRS Clinical Research Center | Coral Gables, FL
G. Walter Canonica, MD
Head of Personalized Medicine Center, Asthma and Allergy | Humanitas Research Hospital, Milan, Italy
